Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend respite was somehow relaxing and refreshing, despite the increasingly tumultuous events occurring in the wider world. Nonetheless, it is time to take a deep breath and get on with the tasks at hand. On that note, we are firing up the trusty coffee kettle for another cup of stimulation — caramel vanilla cream, thank you — and assembling our to-do list. Meanwhile, here are some tidbits to get you going. Hope your day goes well, and stay safe — wear a mask. …

An experimental Eli Lilly (LLY) medicine appeared to slow the decline of patients with the early symptoms of Alzheimer’s disease, STAT writes. The results are likely to generate both excitement and debate, because the study is small — enrolling just 272 patients — and because the medicine, donanemab, is the latest in a line of similar drugs that all target the same basic chemical mechanism, known as beta amyloid. Multiple previous beta amyloid-targeting drugs have failed to reach the market, costing drug makers billions of dollars in wasted research.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.